EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-06-01

Study Completion Date

2031-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this registry is to capture real-world data from plasma- and tissue-based molecular profiling, treatments, outcomes and patient-reported outcomes from patients with advanced or metastatic non-small cell lung cancer (NSCLC). The main objective of the study is to better understand the real-world clinical practice of the use and utility of molecular tumour profiling, the choice of treatment, and the outcome after such molecular profiling and treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Lung Cancer Registry for Lung Cancer Patients

NCT03276429

Lung Cancer

COMPLETED

A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced

NCT06467383

Non-small Cell Lung Cancer NSCLC NSCLC, Stage III +1 more

RECRUITING

Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer

NCT07288632

Venous Thromboembolism (VTE) NSCLC (Advanced Non-small Cell Lung Cancer)

RECRUITING

Distribution and Prognostic Impact of Oncogenic Drivers in Metastatic Lung Adenocarcinoma : a Retrospective Monocentric Study in Nancy University Hospital Center

NCT04493827

Adenocarcinoma of Lung Stage IV Adenocarcinoma of Lung, Response to Tyrosine Kinase Inhibitor in, Somatic

COMPLETED

Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site

NCT07325864

NSCLC Lung Cancer (Diagnosis)

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

NSCLC (Advanced Non-small Cell Lung Cancer)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Advanced NSCLC patients

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Locally advanced or metastatic, unresectable NSCLC, stages IIIB/C or IV, who have not previously been treated for this advanced disease.
* Intention-to-initiate first-line tumour therapy for this advanced disease.
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
* At least 18 years of age on the day of signing informed consent, and capable of signing informed consent.

Exclusion Criteria

* Any known non-cutaneous malignancy (except for this NSCLC and early-stage non-invasive cervical cancer) that has occurred within 5 years prior to enrolment.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No